SCHEMBL19205312

SCHEMBL19205312

CC(C)(C)OC(=O)N1CCC(F)(COc2ccc(F)cc2C2CCCC2)C1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.48
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
PTGDR Q13258 1/20 0.41
CCNT1 O60563 1/20 0.41
CDK9 P50750 1/20 0.41
PDE4B Q07343 2/20 0.41
PDE4A P27815 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
HDAC2 Q92769 2/20 0.40
RORC P51449 2/20 0.39
GPR119 Q8TDV5 1/20 0.39
NTRK1 P04629 2/20 0.39
BRD3 Q15059 1/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
HDAC1 Q13547 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19205379 0.89 PTGDR2 (0.48) PTGDR2CNR1CNR2PTGDRPDE4B
SCHEMBL19205400 0.89 PTGDR2 (0.48) PTGDR2CNR1CNR2PTGDRPDE4B
SCHEMBL19205325 0.85 PTGDR2 (0.55) PTGDR2PTGDRCCNT1CDK9
SCHEMBL19205343 0.83 PTGDR2 (0.46) PTGDR2PTGDRCCNT1CDK9
SCHEMBL19291092 0.81 PTGDR2 (0.48) PTGDR2PTGDRCCNT1CDK9
SCHEMBL19205404 0.79 RBP4 (0.56) PTGDR2CCNT1CDK9PDE4BGPR119
SCHEMBL21722956 0.77 MGLL (0.46) CCNT1HDAC2GPR119HDAC1
SCHEMBL19205396 0.74 PTGDR2 (0.54) PTGDR2PTGDRCCNT1CDK9
SCHEMBL16759103 0.74 SCN9A (0.51)
SCHEMBL4853312 0.74 ALDH1A1 (0.54) CCNT1CDK9PDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3210971-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-10-16 EP disclosed
US-9944596-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-17 US disclosed
EP-3210971-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-08-30 EP disclosed
US-20170233339-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233339-A1 HETEROCYCLIC COMPOUND RBP4, RBP1, RARA PTGDR2 3817/4885CNR1 2702/4885CNR2 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.